Identification | Back Directory | [Name]
3-Pyridazinamine, N,N-dimethyl-6-(2-naphthalenyl)-5-(4-pyridinyl)-, hydrochloride (1:1) | [CAS]
1454658-89-9 | [Synonyms]
MW108 MW-108 MW 108 MW0111108 MW01-11-108 MW01 11 108 3-Pyridazinamine, N,N-dimethyl-6-(2-naphthalenyl)-5-(4-pyridinyl)-, hydrochloride (1:1) | [Molecular Formula]
C21H19ClN4 | [MOL File]
1454658-89-9.mol | [Molecular Weight]
362.86 |
Hazard Information | Back Directory | [Description]
MW108 is an active site targeted, CNS-active, p38αMAPK inhibitor. It acts by ameliorating beta-amyloid induced synaptic and cognitive dysfunction and preventing early memory loss in Alzheimer's disease. | [Uses]
MW108 (MW01-11-108SRM) hydrochloride is a selective and CNS-penetrant p38αMAPK inhibitor with a Ki of 114 nM. MW108 hydrochloride ameliorates beta-amyloid induced synaptic and cognitive dysfunction[1]. | [IC 50]
p38α MAPK: 114 nM (Ki) | [References]
[1] D Martin Watterson, et al. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One. 2013 Jun 26;8(6):e66226. DOI:10.1371/journal.pone.0066226 |
|
|